source
- FDA reexamines previously rejected rare cancer therapy amid claims of political interferenceThe FDA has opened a new review of a treatment for a rare form of cancer that it had turned down a few months earlier. The reconsideration arrives as the agency faces fresh allegations that politi…
- FDA agrees to revisit rare blood cancer drug Ebvallo after companies address concernsTwo companies developing a therapy for a rare blood cancer have reached an agreement with the FDA to address the agency’s concerns about their drug Ebvallo. The FDA had previously rejected Ebvallo…